# GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/glp1-suicidal-ideation-what-happened

> In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.

## Key points

- Removed from the labels of Wegovy, Zepbound and Saxenda in February 2026, verified on all three SPLs.
- 27 RCTs, 59k participants: 0.047 vs 0.042 events per 100 person-years, rate ratio 0.76.
- 298k adults in Swedish and Danish registers: no increase in suicide death; self-harm composite LOWER.
- Only 27 of 144 eligible trials recorded these events at all, and the authors call for continued monitoring.

In February 2026 the Suicidal Behavior and Ideation section was **removed** from the Wegovy, Zepbound and Saxenda labels.[4][5][6] Each of those labels now contains a single mention of the word, in the table recording that the section is gone. That happened after three large studies looked for a signal and none of them found one; one found the opposite. If you have read that these drugs carry a suicidality warning, that was true, and it is not true now.

> **If you are having thoughts of harming yourself, this page is not the thing you need right now.** In the US you can call or text **988** for the Suicide & Crisis Lifeline, any time. Nothing below is a reason to wait, and nothing below means what you are feeling is not real or not urgent.

## Where the concern came from

In 2023 European regulators opened an investigation after reports of suicidal thoughts in people taking semaglutide.[3] That was the right response to a safety signal: reports of that kind are exactly what post-marketing surveillance exists to catch, and the correct next step is to find out whether the drug is causing them or whether they would have occurred anyway in a large population.

There was also a plausible reason to worry. Bariatric surgery, the older standard treatment for obesity, has a small but real association with increased suicidality. A drug producing comparable weight loss raised a reasonable question about whether it might carry a comparable risk.

## What the studies found

*The three largest investigations of this question. None found an increase.*

| Study | Design and size | Result |
| --- | --- | --- |
| JAMA Psychiatry, 2025[1] | Meta-analysis of 27 randomized trials; 32,354 on a GLP-1 against 27,042 on placebo | 0.047 vs 0.042 events per 100 person-years — rate ratio 0.76 (95% CI 0.48–1.21) |
| JAMA Internal Medicine, 2024[2] | Swedish and Danish national registers; 124,517 GLP-1 users against 174,036 on an SGLT2 inhibitor | 77 vs 71 suicide deaths — HR 1.25 (0.83–1.88), not significant |
| Nature Medicine, 2024[3] | 240,618 adults with overweight or obesity, replicated in 1,589,855 with type 2 diabetes | **Lower** risk of suicidal ideation on semaglutide — HR 0.27 incident, 0.44 recurrent |

Read the register study past its headline. Suicide death alone showed no significant difference. The composite of suicide death *and* non-fatal self-harm came out **lower** on GLP-1 drugs, at a hazard ratio of 0.83 (95% CI 0.70–0.97). New diagnoses of depression and anxiety were flat, at 1.01 (0.97–1.06).[2]

Its authors also did what good studies do: they said how much uncertainty is left rather than declaring the matter closed. The upper bound of their confidence interval is compatible with an absolute increase of no more than 0.16 events per 1,000 person-years.[2] That is the ceiling on what the data can still hide.

## The randomized evidence, pooled

A 2025 meta-analysis pooled 25 randomized controlled trials and found **no significant association** between these drugs and suicidal behavior: a risk ratio of 0.84 (95% CI 0.54–1.32, P = 0.46).[7]

What makes it unusually clean is the consistency. No subgroup reached significance, and every one had an I² of **0%**, meaning no detectable variation between studies. The point estimates fall on both sides of 1, scattered around no effect: type 2 diabetes (0.74) and obesity (1.07), adolescents (0.91) and adults (0.84), suicidal ideation (1.04), attempts (0.68) and completed suicides (1.06), and each individual drug from dulaglutide (0.46) to lixisenatide (1.25).

> **Now the limit, which is structural rather than statistical.** Randomized trials of these drugs routinely leave out anyone with a current psychiatric illness or past suicidality. So this pools 25 studies that had systematically screened out the population most at risk. The interval, 0.54 to 1.32, is wide because the events are rare. It is reassuring about the trial population and cannot speak to the group the concern was raised about.

## What the label change says

Each of the three labels carries a Recent Major Changes table at the top, which records what was added or taken out and when. All three record the same thing in February 2026: the Suicidal Behavior and Ideation section, removed.[4][5][6]

> Suicidal Behavior and Ideation (5.10) ……… (Removed) 02/2026
>
> — WEGOVY prescribing information, Recent Major Changes

A regulator removing a warning is a stronger statement than a regulator declining to add one. Warnings are cheap to keep and expensive to take off, because taking one off invites exactly the criticism a regulator least wants. It happened across three products in the same month.

> **We publish this having just corrected ourselves on it.** Our own drug pages still said Zepbound carried “suicidal ideation monitoring recommended” and that Wegovy’s was “under review by FDA”. Both were accurate when written and neither had been re-checked against the current label. They were fixed in the same change that published this page. A safety fact with a date on it needs re-reading, not remembering.

## What this does not settle

- **Only 27 of 144 eligible trials systematically recorded these events.**[1] The meta-analysis is built from the minority of trials that were looking, which is a real limitation and its authors say so.
- **The register study is mostly people with type 2 diabetes**, at a mean age of 60.[2] That is not the same population as a 38-year-old taking Wegovy for weight.
- **Absence of a population signal is not a statement about you.** A drug can fail to raise risk across 300,000 people and still be part of what is happening to one person.
- **Continued monitoring is the authors’ own recommendation**, not a formality, because extended use in far larger numbers is still accumulating.[1]

## If your mood has changed since starting

Tell your prescriber, and do not talk yourself out of it because a study said the risk is not elevated. Population evidence describes populations. Rapid weight loss changes sleep, eating, hormones and how people relate to their bodies, and any of that can move mood without the drug acting on the brain directly.

Stopping abruptly is not obviously the answer either, and it is not a decision to make alone. The same goes for an antidepressant you already take, as covered in [antidepressants and a GLP-1](https://glpwatchdog.org/research/antidepressants-and-a-glp1). What the evidence supports is telling someone, promptly, and letting a clinician who knows your history weigh it. If you are in crisis, **988** in the US is available now, and is the right first call rather than the last one.

## Frequently asked questions

### Do Ozempic and Wegovy cause suicidal thoughts?

The evidence does not support it. A meta-analysis of 27 randomized trials found event rates of 0.047 per 100 person-years on a GLP-1 against 0.042 on placebo, with no significant difference. Swedish and Danish national registers covering nearly 300,000 adults found no increase in suicide death, and a lower rate of the combined suicide-and-self-harm outcome. A 240,000-person cohort found a lower rate of suicidal ideation on semaglutide.

### Is there still a suicide warning on these drugs?

No. The Suicidal Behavior and Ideation section came out of the labels for Wegovy, Zepbound and Saxenda in February 2026, and each label now mentions the word only in the table recording that removal. Many sources still describe the warning as current because it was, until then.

### Why was the warning there in the first place?

European regulators opened an investigation in 2023 after post-marketing reports of suicidal thoughts, which is what surveillance is for. There was also a reasonable prior concern, since bariatric surgery, the older standard treatment for obesity, carries a small association with increased suicidality.

### Should I stop my GLP-1 if my mood has dropped?

That is a decision for you and your prescriber, not one to make alone or from an article. Tell them promptly rather than waiting, and do not dismiss it because studies found no population-level signal; evidence about populations does not describe any individual. If you are in crisis, call or text 988 in the US now.

### Does the research settle it completely?

No, and its authors say so. Only 27 of 144 eligible trials systematically recorded these events, the register data are mostly people with type 2 diabetes at a mean age of 60, and the upper bound of that study's confidence interval still allows an absolute increase of up to 0.16 events per 1,000 person-years. The authors call for continued monitoring.

## References

1. Ebrahimi P, Batlle JC, Ayati A, et al. Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2025. PMID: 40105856. https://pubmed.ncbi.nlm.nih.gov/40105856/
2. Ueda P, Söderling J, Wintzell V, et al. GLP-1 Receptor Agonist Use and Risk of Suicide Death. JAMA Internal Medicine. 2024. PMID: 39226030. https://pubmed.ncbi.nlm.nih.gov/39226030/
3. Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine. 2024. PMID: 38182782. https://pubmed.ncbi.nlm.nih.gov/38182782/
4. Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Recent Major Changes: Suicidal Behavior and Ideation (5.10) removed 02/2026. DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
5. Eli Lilly and Company. ZEPBOUND (tirzepatide) — US Prescribing Information, Recent Major Changes: Suicidal Behavior and Ideation removed 02/2026. DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
6. Novo Nordisk Inc. SAXENDA (liraglutide) — US Prescribing Information, Recent Major Changes: Suicidal Behavior and Ideation (5.9) removed 02/2026 (SPL effective 2026-02-25). DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
7. Chen J, Zhang Q, Wu Q, et al. Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials. Journal of Diabetes. 2025. PMID: 40887719. https://pubmed.ncbi.nlm.nih.gov/40887719/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/glp1-suicidal-ideation-what-happened

Canonical HTML page: https://glpwatchdog.org/research/glp1-suicidal-ideation-what-happened

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
